2013•Unpublished venueRequires access

Trends in Development of Orphan Drugs - A Review

Janodia Manthan D

Open publisher page 0 citations

Abstract

Orphan drugs are pharmaceutical agents that treat rare medical condition known as orphan or rare disease. According to U.S Rare Disease Act of 2002, any disease that affects less than 200,000 patients or 1 in 1500 is termed as a rare disease [1-3]. European Union defines rare disease as a life threatening or chronically debilitating disease which is of such low prevalence that special efforts are needed to address it.” It should affect 1 in 2000 persons [2,3]. European Union definition for rare disease also includes some tropical diseases found in developing countries [3]. There are around 5000-8000 rare diseases reported, out of which only 10% have cures [4]. According to the European Organisation for Rare Disease (EURORDIS) 80% of rare diseases are genetic in nature [5].

About this research paper

What this paper is about

Orphan drugs are pharmaceutical agents that treat rare medical condition known as orphan or rare disease. According to U.S Rare Disease Act of 2002, any disease that affects less than 200,000 patients or 1 in 1500 is termed as a rare disease [1-3]. European Union defines rare disease as a life threatening or chronically debilitating disease which is of such low prevalence that special efforts are needed to address it.” It should affect 1 in 2000 persons [2,3]. European Union definition for rare disease also includes some tropical diseases found in developing countries [3]. There are around 5000-8000 rare diseases reported, out of which only 10% have cures [4]. According to the European Organisation for Rare Disease (EURORDIS) 80% of rare diseases are genetic in nature [5].

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Orphan drugs are pharmaceutical agents that treat rare medical condition known as orphan or rare disease. According to U.S Rare Disease Act of 2002, any disease that affects less than 200,000 patients or 1 in 1500 is termed as a rare disease [1-3]. European Union defines rare disease as a life threatening or chronically debilitating disease which is of such low prevalence that special efforts are needed to address it.” It should affect 1 in 2000 persons [2,3]. European Union definition for rare disease also includes some tropical diseases found in developing countries [3]. There are around 5000-8000 rare diseases reported, out of which only 10% have cures [4]. According to the European Organisation for Rare Disease (EURORDIS) 80% of rare diseases are genetic in nature [5].

Key concepts: Orphan drug, Rare disease, European union, Disease, Medicine, Inherited disease, Bioinformatics, Business

Related papers

Back to paper searchBrowse research topicsOriginal source
Trends in Development of Orphan Drugs - A Review — Research Paper | ScholarLens